Agnes Veyradier
Overview
Explore the profile of Agnes Veyradier including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
155
Citations
2473
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Joly B, Deniau H, Doinel C, Brouillard A, Siguret V, Coppo P, et al.
J Thromb Haemost
. 2025 Mar;
PMID: 40058702
Introduction: Thrombotic thrombocytopenic purpura (TTP) is a thrombotic microangiopathy characterized by a severe functional deficiency of ADAMTS13. Measuring ADAMTS13 activity is crucial for diagnosing TTP (<10 IU/dL), monitoring treatments, and...
2.
Picod A, Joly B, Veyradier A, Coppo P
Stroke
. 2025 Mar;
PMID: 40052283
The 2024 Guidelines for the Primary Prevention of Stroke, recently updated by the American Heart Association and the American Stroke Association, serve as an essential resource for clinicians aiming to...
3.
Weisinger J, Bouzid R, Fadlallah J, Barbet C, Provot F, Poullin P, et al.
Am J Hematol
. 2024 Dec;
100(2):350-353.
PMID: 39668454
No abstract available.
4.
Joly B, Leclercq M, Benhamou Y, Veyradier A, Coppo P
Haematologica
. 2024 Dec;
PMID: 39665201
Not available.
5.
Joly B, Joseph A, Dossier C, Kwon T, Gouge-Biebuyck N, Boyer O, et al.
Rev Med Interne
. 2024 Nov;
PMID: 39578196
Thrombotic Thrombocytopenic Purpura (TTP) is a rare disease characterized by a severe deficiency of ADAMTS13, the specific protease that cleaves von Willebrand factor. The congenital form of TTP (cTTP) results...
6.
Simon D, Leclercq M, Joly B, Veyradier A, Coppo P, Benhamou Y
Haematologica
. 2024 Sep;
PMID: 39323409
In up to 25% of patients with acquired TTP, anti-ADAMTS13 antibodies are not identified, the mechanism resulting from ADAMTS13 deficiency remains unidentified (uTTP). In this study, we provide further insights...
7.
Weisinger J, Bouzid R, Ranta D, Woaye-Hune P, Cohen-Aubart F, Gaible C, et al.
Br J Haematol
. 2024 Sep;
205(5):1951-1958.
PMID: 39228246
The immunosuppressive treatment of immune-mediated thrombotic thrombocytopenic purpura (iTTP) in patients with intolerance or refractoriness to the B-cell depleting monoclonal antibody rituximab remains debated. Daratumumab, a plasma cell-directed monoclonal antibody...
8.
Peronino C, Rivet N, Itzhar-Baikian N, Philippe A, Joly B, Roux de Bezieux J, et al.
Ann Biol Clin (Paris)
. 2024 Aug;
82(4):361-375.
PMID: 39210589
The assessment of von Willebrand factor (VWF) multimer distribution, particularly following the implantation of circulatory support devices, is a crucial parameter in hemostasis. Our study aimed to evaluate the semi-automated...
9.
Luciano J, Gilardin L, Nocturne G, Bouzid R, Veyradier A, Mariette X, et al.
RMD Open
. 2024 Aug;
10(3).
PMID: 39209728
Objectives: The association between immune-mediated thrombotic thrombocytopenic purpura (iTTP) and Sjögren disease (SjD) has been poorly investigated. This study presents the first retrospective cohort of iTTP-SjD aiming to identify risk...
10.
Daniel M, Ternisien C, Castet S, Falaise C, dOiron R, Volot F, et al.
J Thromb Haemost
. 2024 Jul;
22(10):2702-2712.
PMID: 38992343
Background: Type 2 Normandy von Willebrand disease (VWD2N) is usually perceived as a mild bleeding disorder that can be treated with desmopressin (DDAVP). However, VWD2N patients can be compound heterozygous...